Sarah Boyce, Director of Contineum Therapeutics CTNM, has filed 0 purchases and 26 sales on the open market. Over the past 12 months that comes to a net sale of $1.7M. The latest trade was on 06/26.

SB

SB

Sarah Boyce

Director

Company

Contineum Therapeutics CTNM

First filing

23/01/24

Trades

93 trades

Buys / sales

0 / 26

12-month net buying

−$1.7M

Last trade

06/26

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
AB Avidity Biosciences	Open-market sale10b5-1 plan	01/21	01/23	14,387 sh2 trades	$72.45avg.	$1,042,338.15	−5.1%
AB Avidity Biosciences	Open-market sale10b5-1 plan	01/07	01/09	8,576 sh	$72.23	$619,444.48	−2.9%
AB Avidity Biosciences	Open-market sale10b5-1 plan	25/09/05	25/09/05	50,000 sh	$49.95	$2,497,500	−14.1%
AB Avidity Biosciences	Open-market sale10b5-1 plan	25/08/28	25/08/29	25,000 sh	$49.39	$1,234,750	−7.6%
AB Avidity Biosciences	Open-market sale10b5-1 plan	25/03/20	25/03/21	31,540 sh	$31.06	$979,632.4	−9.3%
AB Avidity Biosciences	Open-market sale10b5-1 plan	25/01/21	25/01/23	10,397 sh2 trades	$28.59avg.	$297,250.23	−3.0%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/12/18	24/12/19	31,855 sh	$32.66	$1,040,384.3	−10.7%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/09/23	24/09/23	32,880 sh	$44.00	$1,446,720	−12.3%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/08/06	24/08/07	28,000 sh	$43.35	$1,213,800	−12.0%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/07/09	24/07/11	28,000 sh	$39.93	$1,118,040	−12.0%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/06/18	24/06/20	32,074 sh	$39.13	$1,255,055.62	−18.4%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/06/12–24/06/14	24/06/14	300,000 sh3 trades	$38.63avg.	$11,589,000	−72.8%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/06/04	24/06/05	28,000 sh	$27.42	$767,760	−20.0%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/05/07	24/05/07	28,000 sh	$25.54	$715,120	−20.0%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/04/02	24/04/03	28,000 sh	$26.25	$735,000	−20.0%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/03/08–24/03/12	24/03/12	112,000 sh2 trades	$21.70avg.	$2,430,400	−50.0%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/03/01	24/03/05	84,000 sh	$20.13	$1,690,920	−42.8%
AB Avidity Biosciences	Open-market sale10b5-1 plan	24/01/22	24/01/23	5,092 sh	$10.13	$51,581.96	−10.4%
AB Avidity Biosciences	Open-market sale	23/02/01–23/02/03	23/02/03	50,000 sh3 trades	$24.35avg.	$1,217,596.9	−48.4%